Pfizer PFE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $9.87B-8.6% | $10.79B+36.4% | $7.91B-1.9% | ||
| $6.59B-0.1% | $6.59B-1.6% | $6.7B-1.4% | $6.79B-1.5% | $6.89B-1.7% | ||
| $901M+12.8% | $799M+6.4% | $751M-8.9% | $824M-0.4% | $827M-5.7% | ||
| -$1.48B+30.5% | -$2.13B-1.8% | -$2.1B-15.6% | -$1.81B+22.0% | -$2.32B-10.6% | ||
| —— | $263M+17.1% | $224.5M+20.7% | $186M+26.1% | $147.5M+35.3% | ||
| —— | -$561M-171% | -$207.25M-241% | $146.5M-70.7% | $500.25M-41.4% | ||
| —— | -$469M+22.8% | -$607.5M+18.6% | -$746M+15.7% | -$884.5M+13.5% | ||
| —— | -$1.29B+28.9% | -$1.81B+22.4% | -$2.33B+18.3% | -$2.86B+15.5% | ||
| —— | -$3.67B-3.9% | -$3.53B-4.1% | -$3.39B-4.2% | -$3.25B-4.4% | ||
| —— | -$2.81B-15.0% | -$2.44B-17.6% | -$2.08B-21.3% | -$1.71B-27.1% | ||
| $12.57B+2.3% | $12.29B-10.1% | $13.66B-13.4% | $15.77B+12.7% | $13.99B+9.8% | ||
| $2.5B-4.9% | $2.63B-2.7% | $2.7B-1.8% | $2.75B-0.7% | $2.77B-4.8% | ||
| -$3.84B-184% | -$1.35B— | —— | —— | —— | ||
| -$8.53B+21.8% | -$10.9B+31.9% | -$16.01B+11.9% | -$18.17B-4.2% | -$17.44B-1.7% | ||
| $67M+63.4% | $41M+486% | $7M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $2.68B-2.2% | $2.74B-13.1% | $3.15B-0.2% | $3.16B-0.3% | $3.17B-1.9% | ||
| —— | -$469M+22.8% | -$607.5M+18.6% | -$746M+15.7% | -$884.5M+13.5% | ||
| —— | -$2.81B-15.0% | -$2.44B-17.6% | -$2.08B-21.3% | -$1.71B-27.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | -$1.29B+28.9% | -$1.81B+22.4% | -$2.33B+18.3% | -$2.86B+15.5% | ||
| $603M+28.3% | $470M-78.2% | $2.16B-16.4% | $2.58B+24.7% | $2.07B-8.5% | ||
| —— | —— | —— | —— | —— | ||
| $730M-7.1% | $786M— | —— | —— | —— | ||
| $4.96B-5.9% | $5.27B+30.9% | $4.03B-6.6% | $4.31B-3.2% | $4.45B+4.9% | ||
| —— | —— | —— | —— | -$302M-15,000% | ||
| $14.1B-1.8% | $14.36B-12.9% | $16.48B+10.2% | $14.96B+23.1% | $12.16B+20.0% | ||
| $18.58B+3.5% | $17.96B+21.9% | $14.73B+14.1% | $12.92B+74.0% | $7.43B+79.9% | ||
| $1.1B+0.5% | $1.1B+105% | $533M-62.0% | $1.4B+4.2% | $1.35B-14.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $9.78B+0.1% | $9.77B+0.7% | $9.71B+0.7% | $9.64B+0.7% | $9.58B+0.7% | ||
| -$386M+15.7% | -$458M-6.8% | -$429M-8.1% | -$397M+9.6% | -$439M+6.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $8.57B-33.8% | $12.95B+15.3% | ||
| —— | —— | —— | —— | $219M+23.0% | ||
| $4.61B-1.7% | $4.69B+14.2% | $4.1B-7.0% | $4.41B+23.5% | $3.57B-0.9% | ||
| —— | —— | —— | —— | $11.22B+14.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Pfizer generate?
- Pfizer (PFE) generated $12.6B in operating cash flow over the trailing twelve months.
- What is Pfizer's free cash flow?
- After $2.5B of capital expenditures, Pfizer's free cash flow was $12.5B over the trailing twelve months, up 26.6% year over year.
- Where does Pfizer's cash flow data come from?
- Every line is extracted from Pfizer's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
